Pretomanid Price Cut By 34% But Access Complexities Remain
Viatris, MedAccess and TB Alliance deal to lower the price of pretomanid, a key drug used as part of a shorter all-oral drug regime for multidrug-resistant TB, but country-level prioritization and uptake of the treatment option will be pivotal to widen access sharply.
You may also be interested in...
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
While Viatris says it has sufficient capacity to meet current and future demand for tuberculosis drug pretomanid, TB Alliance has signed a non-exclusive license with Lupin. This is the second tie-up with an Indian manufacturer but the local restricted use approval means countries other than India are likely to benefit for now.
TB Alliance CEO Mel Spigelman discusses a range of new and evolving aspects pertaining to the three-drug BPaL regimen for highly drug-resistant TB, including the ZeNix trial results and adding a licensee for pretomanid. He also notes how COVID-19 has had a “terrible impact” on efforts to tackle the TB pandemic.